Advertisement

Hypo- und Depigmentierungen

  • Wilhelm Stolz
Conference paper
Part of the Fortschritte der praktischen Dermatologie und Venerologie book series (DERMATOLOGIE, volume 13)

Zusammenfassung

Pigmentstörungen beschäftigen die Menschen schon seit Jahrtausenden. Bereits im Ebers Papyrus, der etwa um 1450 v. Chr. entstand, wird die Vitiligo erwähnt [5]. Auch im Alten Testament werden im Buch Levitikus, Kapitel XIII, ausführliche Verhaltensmaßregeln gegeben, wie beim Auftreten von Pigmentstörungen zu verfahren sei. Schon aus diesen alten Berichten läßt sich erkennen, welcher enormen psychischen Belastung damals und heute Patienten mit Pigmentstörungen ausgesetzt sind.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bolognia JL, Pawelek JW (1988) Biology of hypopigmentation. J Am Acad Dermatol 19:217–255PubMedCrossRefGoogle Scholar
  2. 2.
    Cormane RH, Siddiqui AH, Westerhof W, Shutgens RBH (1985) Phenylalanine and UVA for the treatment of vitiligo. Arch Dermatol Res 277:126–130PubMedCrossRefGoogle Scholar
  3. 3.
    Fleischman RA, Saltman DL, Stastny V, Zneimer S (1991) Deletion of the c-kit protooncogene in the human developmental defect piebald trait. Proc Natl Acad Sci 88:10885–10889PubMedCrossRefGoogle Scholar
  4. 4.
    Giebel LB, Spritz RA (1991) Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci 88:8696–8699PubMedCrossRefGoogle Scholar
  5. 5.
    Goldman L, Moraites RS, Kitzmiller KW (1966) White spots in biblical times. Arch Dermatol 93:744–753PubMedCrossRefGoogle Scholar
  6. 6.
    Goldstein E, Haberman HF, Menon IA (1992) Non-psoralen treatment of vitiligo. Part I. Cosmetics, systemic coloring agents, and corticosteroids. Int J Dermatol 31:229–236PubMedCrossRefGoogle Scholar
  7. 7.
    Goldstein E, Haberman HF, Menon IA (1992) Non-psoralen treatment of vitiligo. Part II. Less commonly used and experimental therapies. Int J Dermatol 31:314–319PubMedCrossRefGoogle Scholar
  8. 8.
    King RA, Mentink MM, Oetting WS (1991) Non-random distribution of missense mutations within the human tyrosinase gene in type I (tyrosinase-related) oculocutaneous albinism. Mol Biol Med 8:19–29PubMedGoogle Scholar
  9. 9.
    Mosher DB, Fitzpatriek TB, Ortonne JP, Hori Y (1987) Disorders of pigmentation. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF (eds) Dermatology in general medicine. McGraw-Hill, New York St Louis San Francisco, pp 794–838Google Scholar
  10. 10.
    Ortel B, Tanew A, Hönigsmann H (1988) Treatment of vitiligo with khellin and ultraviolet A. J Am Acad Dermatol 18:693–701PubMedCrossRefGoogle Scholar
  11. 11.
    Plott RT, Wagner RF (1990) Modern treatment approaches to vitiligo. Cutis 45:311–316PubMedGoogle Scholar
  12. 12.
    Schallreuter KU (1992) Klinik und Pathogenese der Vitiligo. In: Macher E, Kolde G, Bröcker EB (Hrsg) Jahrbuch der Dermatologie 1991/1992. Biermann, Zülpich, S 121 - 140Google Scholar
  13. 13.
    Schallreuter KU, Witkop CJ (1988) Thioredoxin reductase activity in Hermansky-Pudlak syndrome. A method for identification of putative heterozygotes. J Invest Dermatol 90:372–377PubMedCrossRefGoogle Scholar
  14. 14.
    Stolz W, Graubner U, Gerstmeier J, Burg G, Belohradsky B (1989) Chediak-Higashi syndrome: approaches in diagnosis and treatment. In: Fritsch P, Schuler G, Hintner H (eds) Immunodeficiency and Skin. Curr Probi Dermatol. Karger, Basel, pp 93–100Google Scholar
  15. 15.
    Thiele B (1991) Klinik und Therapie der Vitiligo. Dtsch Med Wschr 116:1025–1029PubMedCrossRefGoogle Scholar
  16. 16.
    Witkop CJ, Quevedo WC, Fitzpatrick TB, King RA (1989) Albinism. In: Scriver CS, Beaudet AL, Sly WS, Valle D (eds) The metabolic basis of inherited disease. McGraw-Hill, New York St. Louis San Francisco, pp 2905–2947Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • Wilhelm Stolz

There are no affiliations available

Personalised recommendations